Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations

J Clin Oncol. 2017 Feb 20;35(6):689-690. doi: 10.1200/JCO.2016.70.1607. Epub 2016 Dec 5.

Authors

Andrea Wang-Gillam¹, Daniel Von Hoff¹, Jens Siveke¹, Richard Hubner¹, Bruce Belanger¹, J Marc Pipas¹, Li-Tzong Chen¹

Affiliation

¹ Andrea Wang-Gillam, Washington University School of Medicine, St. Louis, MO; Daniel Von Hoff, TGen, Phoenix; and HonorHealth, Scottsdale, AZ; Jens Siveke, Klinikum rechts der Isar der T U München, Germany; Richard Hubner, The Christie NHS Foundation Trust, Manchester, United Kingdom; Bruce Belanger and J. Marc Pipas, Merrimack Pharmaceuticals, Cambridge, MA; and Li-Tzong Chen, National Health Research Institutes, Tainan, Taiwan.

PMID: 27918719
DOI: 10.1200/JCO.2016.70.1607

No abstract available

Publication types

Letter
Comment

MeSH terms

Camptothecin
Humans
Irinotecan*
Medical Oncology
Pancreatic Neoplasms*
United States

Substances

Irinotecan
Camptothecin